Glioblastoma Clinical Trials: Current Landscape and Opportunities for Improvement

Stephen J. Bagley, Shawn Kothari, Rifaquat Rahman, Eudocia Q. Lee, Gavin P. Dunn, Evanthia Galanis, Susan M. Chang, Louis Burt Nabors, Manmeet S. Ahluwalia, Roger Stupp, Minesh P. Mehta, David A. Reardon, Stuart A. Grossman, Erik P. Sulman, John H. Sampson, Simon Khagi, Michael Weller, Timothy F. Cloughesy, Patrick Y. Wen, Mustafa Khasraw

Research output: Contribution to journalReview articlepeer-review


Therapeutic advances for glioblastoma have been minimal over the past 2 decades. In light of the multitude of recent phase III trials that have failed to meet their primary endpoints following promising preclinical and early-phase programs, a Society for Neuro-Oncology Think Tank was held in November 2020 to prioritize areas for improvement in the conduct of glioblastoma clinical trials. Here, we review the literature, identify challenges related to clinical trial eligibility criteria and trial design in glioblastoma, and provide recommendations from the Think Tank. In addition, we provide a data-driven context with which to frame this discussion by analyzing key study design features of adult glioblastoma clinical trials listed on as “recruiting” or “not yet recruiting” as of February 2021.

Original languageEnglish (US)
Pages (from-to)594-602
Number of pages9
JournalClinical Cancer Research
Issue number4
StatePublished - Feb 15 2022

ASJC Scopus subject areas

  • General Medicine


Dive into the research topics of 'Glioblastoma Clinical Trials: Current Landscape and Opportunities for Improvement'. Together they form a unique fingerprint.

Cite this